Skip to content
Evigrade
MajorClass Ic antiarrhythmic×Non-selective beta blocker with class III antiarrhythmic activity

Updated · Methodology

Mechanism

Sotalol is a beta-blocker with class III antiarrhythmic properties: it slows the heart rate, prolongs the QT interval and can cause torsade de pointes (sotalol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Flecainide is a class Ic antiarrhythmic. It slows conduction in the heart and lengthens the PR, QRS and QT intervals. Most of the QT increase comes from QRS widening. Rare cases of torsade de pointes have occurred with flecainide (flecainide label, US Food and Drug Administration, FDA). The Spanish sotalol SmPC names flecainide among the QT-prolonging drugs whose combination with sotalol is not recommended. It also lists class Ic antiarrhythmics, which include flecainide, among drugs that slow the heart rate and so raise the risk of torsade de pointes (sotalol SmPC, AEMPS). Both drugs weaken heart muscle contraction, and the negative inotropic effects of flecainide and beta-blockers may add up (flecainide SmPC, AEMPS).

Symptoms

QT prolongation and QRS widening cause no symptoms by themselves and show only on the electrocardiogram (ECG). Torsade de pointes and other ventricular arrhythmias cause palpitations, dizziness and fainting and, in rare cases, progress to ventricular fibrillation (sotalol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Both drugs can cause marked bradycardia, sinus pauses, sinus arrest and second- or third-degree atrioventricular block (sotalol and flecainide labels, US Food and Drug Administration, FDA). New or worsening heart failure causes breathlessness and swelling. During flecainide treatment, it has appeared from a few hours to several months after the start (flecainide FDA label).

Management

Avoid the combination where possible. The Spanish sotalol summary of product characteristics (SmPC) lists flecainide among QT-prolonging drugs whose combination with sotalol is not recommended. It says to give sotalol with these drugs only with extreme caution (sotalol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). A generic sotalol SmPC says under the same heading that sotalol should not be combined with flecainide (generic sotalol SmPC, AEMPS). The US sotalol label says to avoid class I antiarrhythmics with sotalol and to stop them at least three half-lives before the first sotalol dose (sotalol label, US Food and Drug Administration, FDA). If the combination cannot be avoided, monitor the patient clinically and with regular electrocardiograms (ECGs) (sotalol SmPC, AEMPS). Start sotalol and increase its dose in a setting where heart rhythm can be monitored. Before that, record an ECG with QT measurement and assess kidney function and electrolytes (sotalol SmPC, AEMPS). Correct low potassium and magnesium before sotalol, and any potassium or other electrolyte imbalance before flecainide (sotalol and flecainide SmPCs, AEMPS). If QRS or QT lengthens by 25% or more, PQ by 50% or more, or the corrected QT interval (QTc) exceeds 480 ms, reassess the benefit and risk of sotalol. In that case, seriously consider a lower dose or withdrawal (sotalol SmPC, AEMPS). If PR reaches 0.3 seconds or QRS 0.18 seconds, continue flecainide with caution and consider a lower dose. With second- or third-degree atrioventricular block, or right bundle branch block with left hemiblock, stop flecainide unless a pacemaker is in place (flecainide FDA label). Watch for signs of heart failure and stop sotalol if they appear (sotalol FDA label). In heart failure, monitor flecainide plasma levels when feasible and keep trough levels below 0.7–1 mcg/mL (flecainide FDA label).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Flecainide

Other interactions with Sotalol